Benjamin I. Morris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin I. Morris has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alberto G. Conti
Department of Pathology, University of Cambridge, Cambridge, UK
30 shared publications - Alexander C. Evans
Department of Pathology, University of Cambridge, Cambridge, UK
30 shared publications - Alexander J. Wesolowski
Department of Pathology, University of Cambridge, Cambridge, UK
30 shared publications - Charlotte J. Imianowski
Department of Pathology, University of Cambridge, Cambridge, UK
30 shared publications - Edmund Poon
F-Star Therapeutics, Babraham Research Campus, Cambridgeshire, United Kingdom. 3
30 shared publications - Jie Yang
Department of Pathology, University of Cambridge, Cambridge, UK
30 shared publications
Latest Publications
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- Open Access
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Data from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.
- 28 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- Open Access
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.
- 17 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Supplementary Figure 1: OX40 and CD137 are highly expressed on Treg cells. Representative plots showing OX40+ (left) and CD137+ (right) SP resting or activated cells from the spleen and tumor on day 18 post tumor implantation. ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. One-way ANOVA with Tukey’s correction for multiple comparisons. Bars and error are mean and s.e.m.